Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 11Completed 8Recruiting 5Active not recruiting 2Withdrawn 1Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 4Thoracic 1Gastrointestinal 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 250Lung Neoplasms 176Small Cell Lung Carcinoma 37Breast Neoplasms 37Neoplasms 25Neoplasm Metastasis 19Adenocarcinoma of Lung 17Ovarian Neoplasms 14Mesothelioma, Malignant 14Melanoma 13Stomach Neoplasms 12Mesothelioma 12Brain Neoplasms 12Squamous Cell Carcinoma of Head and Neck 11Colorectal Neoplasms 11Prostatic Neoplasms 10Esophageal Neoplasms 10Pancreatic Neoplasms 9Carcinoma, Renal Cell 9Lung Diseases 7Head and Neck Neoplasms 7Colonic Neoplasms 7Uterine Cervical Neoplasms 6Urinary Bladder Neoplasms 6Triple Negative Breast Neoplasms 5Thymoma 5Sarcoma 5Pleural Effusion, Malignant 5Carcinoma, Ovarian Epithelial 5Carcinoma 5

Interventions

Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Neoplastic Cells, Circulating × Thoracic × Clear all
NCT04648189 2023-10-19

Cetuxibab to Reduce Circulating Tumor Cells in Early Stage NSCLC

The Netherlands Cancer Institute

Phase 2 Withdrawn
Thoracic

Lung Neoplasms, Neoplastic Cells, Circulating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡